US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gyre Therapeutics

7.54

-0.1500-1.95%

Volume:59.72K

Turnover:453.78K

Market Cap:726.35M

PE:192.64

High:7.88

Open:7.77

Low:7.48

Close:7.69

52wk High:14.42

52wk Low:6.11

Shares:96.33M

Float Shares:25.95M

Volume Ratio:0.67

T/O Rate:0.23%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.0391

EPS(LYR):0.1420

ROE:10.02%

ROA:5.29%

PB:7.13

PE(LYR):53.09

Loading ...

Overview Company News Filings

US High Growth Tech Stocks to Watch

Simply Wall St.

Exploring High Growth Tech Stocks in the US Market

Simply Wall St.

Gyre Therapeutics Reports Strong Q3 2025 Results

Gyre Therapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview

Gyre Therapeutics Q3 EPS $0.03 Beats $(0.02) Estimate, Sales $30.600M Miss $32.930M Estimate

Gyre Therapeutics reports Q3 revenue of $30.6 million and net income of $5.9 million

Gyre Therapeutics: FY Revenue Guidance Revised to $115–118 Mln

THOMSON REUTERS

Gyre Therapeutics: Expect to File the US Ind for Hydronidone for Treatment of Mash-Associated Liver Fibrosis in 2026

THOMSON REUTERS

Gyre Therapeutics Q3 Net Income USD 5.936 Million

THOMSON REUTERS

Gyre Therapeutics Inc FY2025 REV View $119.5 Mln -- Lseg Ibes Data

THOMSON REUTERS

Gyre Therapeutics: Guidance Reflects Slower-Than-Expected Commercialization of Etorel Due to Uncertainty Related to China’s Centralized Procurement Policy

THOMSON REUTERS

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

THOMSON REUTERS

Noble Financial Sticks to Their Buy Rating for Gyre Therapeutics (GYRE)

Gyre Therapeutics Subsidiary Completes Enrollment in Phase 3 Trial of Pirfenidone Capsules for Pneumoconiosis

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

THOMSON REUTERS

High Growth US Tech Stocks To Watch In October 2025

Simply Wall St.

Gyre Therapeutics to Present Positive Phase 3 Trial Results of Hydronidone for Liver Fibrosis in Chronic Hepatitis B at AASLD 2025

Gyre Therapeutics Initiated at Buy by Jefferies

Jefferies Initiates Coverage on Gyre Therapeutics With Buy Rating, $16 Price Target

MT Newswires Live

Discovering 3 Undiscovered Gems In The US Market

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GYRE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","market":"US","secType":"STK","nameCN":"Gyre Therapeutics","latestPrice":7.54,"timestamp":1765832400000,"preClose":7.69,"halted":0,"volume":59715,"delay":0,"floatShares":25945800,"shares":96333200,"eps":0.039141,"marketStatus":"Pre-Mkt","change":-0.15,"latestTime":"12-16 05:26:43 EST","open":7.77,"high":7.8846,"low":7.475,"amount":453776.7673,"amplitude":0.053264,"askPrice":8.29,"askSize":225,"bidPrice":6.78,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.039141,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765895400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":7.54,"postHourTrading":{"tag":"盘后","latestPrice":7.54,"preClose":7.54,"latestTime":"16:10 EST","volume":574,"amount":4327.96,"timestamp":1765833005067},"volumeRatio":0.6710862567853036,"impliedVol":1.7906,"impliedVolPercentile":0.9653},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","floatShares":25945800,"roa":"5.29%","roe":"10.02%","lyrEps":0.142017,"volumeRatio":0.6710862567853036,"shares":96333200,"dividePrice":0,"high":7.8846,"amplitude":0.053264,"preClose":7.69,"low":7.475,"week52Low":6.11,"pbRate":"7.13","psRate":"6.77","week52High":14.4228,"institutionHeld":0.0987,"latestPrice":7.54,"committee":-0.384615,"eps":0.039141,"divideRate":0,"volume":59715,"delay":0,"ttmEps":0.039141,"open":7.77,"prevYearClose":12.1,"prevWeekClose":7.69,"prevMonthClose":7.75,"prevQuarterClose":7.46,"fiveDayClose":8.16,"twentyDayClose":7.99,"sixtyDayClose":7.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-07","symbol":"GYRE","fiscalQuarterEnding":"2025/09","expectedEps":0.05,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":0.05},{"market":"US","date":"2025-08-11","symbol":"GYRE","fiscalQuarterEnding":"2025/06","expectedEps":0.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":0.02},{"market":"US","date":"2025-05-09","symbol":"GYRE","fiscalQuarterEnding":"2025/03","expectedEps":0.03,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746763200000,"reportTimeType":"pre","actualEps":0},{"market":"US","date":"2025-03-17","symbol":"GYRE","fiscalQuarterEnding":"2024/12","expectedEps":0.04,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"post","actualEps":0.01},{"date":"2025-02-18","symbol":"GYRE","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739869200000,"name":null,"time":"Pre-Market","dateTimestamp":1739854800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1760245200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GYRE","date":"2025-12-15","current":192.636877,"percent":0.759124,"low":-11548.718266,"twenty":-15.279098,"median":-10.271,"eighty":109.817336,"high":193.429414,"avg":-785.440798,"sd":2678.689055,"marketCap":698947029},"quantilePoints":[{"date":"2024-04-05","current":-15.607876,"twenty":-15.830217,"median":-15.617068,"eighty":-15.398378,"marketCap":1450486717},{"date":"2024-04-12","current":-31.76291,"twenty":-32.589325,"median":-21.429161,"eighty":-15.61523,"marketCap":1405212396},{"date":"2024-04-19","current":-29.754799,"twenty":-32.477335,"median":-30.585076,"eighty":-15.742078,"marketCap":1316372220},{"date":"2024-04-26","current":-31.531205,"twenty":-31.948274,"median":-30.797472,"eighty":-16.000876,"marketCap":1394961607},{"date":"2024-05-03","current":-27.239192,"twenty":-31.948274,"median":-30.778163,"eighty":-24.631989,"marketCap":1205080075},{"date":"2024-05-10","current":-14.851474,"twenty":-31.774495,"median":-30.223912,"eighty":-24.631989,"marketCap":1301657414},{"date":"2024-05-17","current":-14.909982,"twenty":-31.744918,"median":-29.754799,"eighty":-15.561911,"marketCap":1306785414},{"date":"2024-05-24","current":-12.302842,"twenty":-31.573048,"median":-28.630129,"eighty":-14.89828,"marketCap":1078282562},{"date":"2024-05-31","current":-8605.737804,"twenty":-32.075712,"median":-29.501562,"eighty":-15.108912,"marketCap":890160307},{"date":"2024-06-07","current":-8895.075775,"twenty":-32.90985,"median":-30.136978,"eighty":-15.311743,"marketCap":920088848},{"date":"2024-06-14","current":-9126.546144,"twenty":-8519.763095,"median":-30.585076,"eighty":-15.366351,"marketCap":944031680},{"date":"2024-06-21","current":-8961.210165,"twenty":-8885.155616,"median":-30.816781,"eighty":-15.424018,"marketCap":926929657},{"date":"2024-06-28","current":-8175.864257,"twenty":-8865.315298,"median":-30.894016,"eighty":-15.515947,"marketCap":845695047},{"date":"2024-07-05","current":-9688.68848,"twenty":-8961.210165,"median":-31.531205,"eighty":-15.611553,"marketCap":1002178559},{"date":"2024-07-12","current":-10424.433593,"twenty":-9151.346542,"median":-31.791873,"eighty":-15.679573,"marketCap":1078282562},{"date":"2024-07-15","current":-11094.044316,"twenty":-9210.867496,"median":-31.820836,"eighty":-15.710825,"marketCap":1147545756},{"date":"2024-08-02","current":-11548.718266,"twenty":-9298.495565,"median":-32.139431,"eighty":-15.742078,"marketCap":1194576320},{"date":"2024-08-09","current":-8374.267436,"twenty":-9189.373818,"median":-32.728348,"eighty":-16.000876,"marketCap":866217475},{"date":"2024-08-16","current":-10.635127,"twenty":-9134.812943,"median":-32.641458,"eighty":-15.61523,"marketCap":914301855},{"date":"2024-08-23","current":-11.421808,"twenty":-9126.546144,"median":-31.820836,"eighty":-15.175222,"marketCap":981932798},{"date":"2024-08-30","current":-13.672312,"twenty":-9020.73112,"median":-31.635813,"eighty":-14.375603,"marketCap":1175408659},{"date":"2024-09-06","current":-11.770337,"twenty":-8974.437045,"median":-30.942288,"eighty":-13.816505,"marketCap":1011895874},{"date":"2024-09-13","current":-14.920484,"twenty":-8961.210165,"median":-30.778163,"eighty":-13.696211,"marketCap":1282714046},{"date":"2024-09-20","current":-15.572509,"twenty":-8941.369845,"median":-30.223912,"eighty":-13.816505,"marketCap":1338768556},{"date":"2024-09-27","current":-13.909847,"twenty":-8923.182886,"median":-29.754799,"eighty":-13.90034,"marketCap":1195829555},{"date":"2024-10-04","current":-13.312158,"twenty":-8919.876167,"median":-28.630129,"eighty":-13.654308,"marketCap":1144446254},{"date":"2024-10-11","current":-12.327984,"twenty":-8904.995932,"median":-26.800559,"eighty":-13.325198,"marketCap":1059836795},{"date":"2024-10-18","current":-15.235629,"twenty":-8865.315298,"median":-15.915547,"eighty":-13.300875,"marketCap":1309807059},{"date":"2024-10-25","current":-15.300832,"twenty":-8830.594739,"median":-15.607876,"eighty":-13.325198,"marketCap":1315412510},{"date":"2024-10-31","current":-15.985457,"twenty":-8804.140979,"median":-15.617068,"eighty":-13.405529,"marketCap":1374269746},{"date":"2024-11-08","current":-16.365804,"twenty":-8779.340581,"median":-15.748988,"eighty":-13.558712,"marketCap":1406968211},{"date":"2024-11-15","current":-13.372591,"twenty":-8709.89947,"median":-15.77333,"eighty":-13.558712,"marketCap":1187780244},{"date":"2024-11-22","current":-11.353175,"twenty":-8602.431085,"median":-15.627389,"eighty":-13.295234,"marketCap":1008411696},{"date":"2024-11-29","current":-12.087508,"twenty":-8556.137012,"median":-15.590193,"eighty":-13.126615,"marketCap":1073636622},{"date":"2024-12-06","current":-10.111572,"twenty":-8387.494312,"median":-15.378053,"eighty":-12.781935,"marketCap":898130076},{"date":"2024-12-13","current":-9.449706,"twenty":-8374.267436,"median":-15.329691,"eighty":-12.475931,"marketCap":839341820},{"date":"2024-12-20","current":-10.299987,"twenty":-8344.506959,"median":-15.279098,"eighty":-12.329976,"marketCap":914865419},{"date":"2024-12-27","current":-12.686569,"twenty":-8225.465052,"median":-15.246496,"eighty":-12.302842,"marketCap":1126846431},{"date":"2025-01-03","current":-11.594732,"twenty":-8192.397854,"median":-15.235629,"eighty":-12.152426,"marketCap":1029867264},{"date":"2025-01-10","current":-9.29511,"twenty":-8179.170976,"median":-15.105225,"eighty":-11.98162,"marketCap":825610256},{"date":"2025-01-17","current":-10.435259,"twenty":-3290.168076,"median":-14.953086,"eighty":-11.68749,"marketCap":926880537},{"date":"2025-01-24","current":-10.242013,"twenty":-32.95233,"median":-14.893499,"eighty":-11.536758,"marketCap":909716083},{"date":"2025-01-31","current":-11.111618,"twenty":-32.786274,"median":-14.681409,"eighty":-11.380628,"marketCap":986956128},{"date":"2025-02-07","current":-12.319402,"twenty":-32.658836,"median":-14.539395,"eighty":-11.347378,"marketCap":1094233968},{"date":"2025-02-14","current":-11.382162,"twenty":-32.515952,"median":-14.451664,"eighty":-11.279742,"marketCap":1010986364},{"date":"2025-02-21","current":-12.135819,"twenty":-32.330588,"median":-14.072853,"eighty":-11.345445,"marketCap":1077927736},{"date":"2025-02-28","current":-10.90871,"twenty":-31.809251,"median":-13.976035,"eighty":-11.179254,"marketCap":968933450},{"date":"2025-03-07","current":-10.338636,"twenty":-31.758412,"median":-13.909847,"eighty":-11.12128,"marketCap":918298310},{"date":"2025-03-14","current":-11.556083,"twenty":-31.698577,"median":-13.789262,"eighty":-11.11355,"marketCap":1026434373},{"date":"2025-03-21","current":79.165838,"twenty":-31.423076,"median":-13.627303,"eighty":-11.045914,"marketCap":956719157},{"date":"2025-03-28","current":70.412668,"twenty":-30.971251,"median":-13.353241,"eighty":-10.90871,"marketCap":850937097},{"date":"2025-04-04","current":52.673943,"twenty":-30.878569,"median":-13.283951,"eighty":-10.748316,"marketCap":636564605},{"date":"2025-04-11","current":56.469566,"twenty":-30.809057,"median":-13.129602,"eighty":-10.622099,"marketCap":682434702},{"date":"2025-04-17","current":61.504575,"twenty":-30.778163,"median":-12.849861,"eighty":-10.560868,"marketCap":743282789},{"date":"2025-04-25","current":70.645053,"twenty":-30.585076,"median":-12.780906,"eighty":-10.377285,"marketCap":853745471},{"date":"2025-05-02","current":72.449806,"twenty":-30.310846,"median":-12.626921,"eighty":-10.338636,"marketCap":875555902},{"date":"2025-05-09","current":73.535777,"twenty":-30.136978,"median":-12.473999,"eighty":-10.164715,"marketCap":888679866},{"date":"2025-05-16","current":132.923099,"twenty":-29.947887,"median":-12.417259,"eighty":-9.938068,"marketCap":963825388},{"date":"2025-05-23","current":136.20365,"twenty":-29.754799,"median":-12.327984,"eighty":-9.652614,"marketCap":987612669},{"date":"2025-05-30","current":117.840031,"twenty":-29.349619,"median":-12.308068,"eighty":-9.440044,"marketCap":854458067},{"date":"2025-06-06","current":99.64599,"twenty":-28.753768,"median":-12.251767,"eighty":50.257139,"marketCap":722533070},{"date":"2025-06-13","current":100.896253,"twenty":-28.630129,"median":-12.168656,"eighty":56.159719,"marketCap":731598729},{"date":"2025-06-20","current":104.146938,"twenty":-27.795567,"median":-12.087508,"eighty":59.335648,"marketCap":755169444},{"date":"2025-06-27","current":92.269436,"twenty":-26.976012,"median":-11.969641,"eighty":62.92987,"marketCap":669045678},{"date":"2025-07-03","current":101.646411,"twenty":-26.790554,"median":-11.75017,"eighty":66.71,"marketCap":737038125},{"date":"2025-07-11","current":97.645568,"twenty":-23.367997,"median":-11.701017,"eighty":68.524795,"marketCap":708028014},{"date":"2025-07-18","current":92.394462,"twenty":-17.913275,"median":-11.686523,"eighty":70.505622,"marketCap":669952244},{"date":"2025-07-25","current":92.269436,"twenty":-17.24169,"median":-11.594732,"eighty":71.634434,"marketCap":669045678},{"date":"2025-08-01","current":88.143567,"twenty":-16.863516,"median":-11.531927,"eighty":73.525921,"marketCap":639129001},{"date":"2025-08-08","current":90.018962,"twenty":-16.53533,"median":-11.498109,"eighty":77.782591,"marketCap":652727491},{"date":"2025-08-15","current":179.246974,"twenty":-16.326683,"median":-11.42614,"eighty":87.268382,"marketCap":746563646},{"date":"2025-08-22","current":164.643977,"twenty":-16.268001,"median":-11.353175,"eighty":89.218793,"marketCap":685742166},{"date":"2025-08-29","current":180.563196,"twenty":-16.183906,"median":-11.256552,"eighty":90.29402,"marketCap":752045713},{"date":"2025-09-05","current":165.298192,"twenty":-16.049822,"median":-11.217903,"eighty":91.769331,"marketCap":688466969},{"date":"2025-09-12","current":177.074053,"twenty":-16.011538,"median":-11.179254,"eighty":92.594504,"marketCap":737513429},{"date":"2025-09-19","current":167.696978,"twenty":-15.943032,"median":-11.12128,"eighty":93.569709,"marketCap":698457915},{"date":"2025-09-26","current":158.974119,"twenty":-15.763593,"median":-11.111618,"eighty":95.145041,"marketCap":662127204},{"date":"2025-10-03","current":163.989763,"twenty":-15.70726,"median":-11.048813,"eighty":96.920416,"marketCap":683017363},{"date":"2025-10-10","current":155.921118,"twenty":-15.633582,"median":-10.966684,"eighty":99.846032,"marketCap":649411455},{"date":"2025-10-17","current":190.594485,"twenty":-15.61523,"median":-10.876478,"eighty":100.896253,"marketCap":793826030},{"date":"2025-10-24","current":179.472839,"twenty":-15.600803,"median":-10.763776,"eighty":101.646411,"marketCap":747504374},{"date":"2025-10-31","current":166.824692,"twenty":-15.546428,"median":-10.691308,"eighty":105.447211,"marketCap":694824844},{"date":"2025-11-07","current":160.064476,"twenty":-15.429294,"median":-10.618842,"eighty":111.643728,"marketCap":666668543},{"date":"2025-11-14","current":110.418625,"twenty":-15.377823,"median":-10.570531,"eighty":112.102687,"marketCap":734394278},{"date":"2025-11-21","current":102.355879,"twenty":-15.373231,"median":-10.435259,"eighty":110.254637,"marketCap":680768953},{"date":"2025-11-28","current":105.908954,"twenty":-15.35855,"median":-10.377285,"eighty":109.598685,"marketCap":704400452},{"date":"2025-12-05","current":107.958805,"twenty":-15.300832,"median":-10.338636,"eighty":109.462028,"marketCap":718034009},{"date":"2025-12-12","current":107.548834,"twenty":-15.279098,"median":-10.299987,"eighty":109.871999,"marketCap":715307298},{"date":"2025-12-15","current":105.089014,"twenty":-15.279098,"median":-10.271,"eighty":109.817336,"marketCap":698947029}],"updateTime":1765880029775},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GYRE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2591625097","title":"US High Growth Tech Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2591625097","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591625097?lang=en_us&edition=fundamental","pubTime":"2025-12-16 01:09","pubTimestamp":1765818555,"startTime":"0","endTime":"0","summary":"The United States market has recently experienced declines in major stock indexes, with technology shares exerting downward pressure on the Nasdaq amid concerns about an AI bubble. In this environment, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and resilience against broader market volatility.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/us-high-growth-tech-stocks-to-watch-8","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/us-high-growth-tech-stocks-to-watch-8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["KNSA","BK4505","GYRE","BK4139","ALLT","BK4097"],"gpt_icon":0},{"id":"2583506655","title":"Exploring High Growth Tech Stocks in the US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506655","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506655?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:08","pubTimestamp":1763118488,"startTime":"0","endTime":"0","summary":"The U.S. stock market recently experienced a significant downturn, with major indices such as the Nasdaq and S&P 500 closing sharply lower, driven by a notable decline in technology shares. In this environment of heightened volatility and economic uncertainty, identifying high-growth tech stocks requires careful consideration of their potential for innovation and resilience amidst broader market fluctuations.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/exploring-high-growth-tech-stocks-in-the-us-market-20","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/exploring-high-growth-tech-stocks-in-the-us-market-20","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","GYRE","SVRA","KNSA","BK4139"],"gpt_icon":0},{"id":"2581395859","title":"Gyre Therapeutics Reports Strong Q3 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581395859","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581395859?lang=en_us&edition=fundamental","pubTime":"2025-11-08 12:19","pubTimestamp":1762575569,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc ( ($GYRE) ) has released its Q3 earnings. Here is a breakdown of the information Gyre Therapeutics Inc presented to its inves...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-reports-strong-q3-2025-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-reports-strong-q3-2025-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2581414887","title":"Gyre Therapeutics Inc  expected to post earnings of 4 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581414887","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581414887?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:38","pubTimestamp":1762533484,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc  expected to post earnings of4cents a share - Earnings Preview Gyre Therapeutics Inc GYRE.OQ GYRE.O is expected to  show a rise in quarterly revenue when it reports  results on N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ2DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2581001877","title":"Gyre Therapeutics Q3 EPS $0.03 Beats $(0.02) Estimate, Sales $30.600M Miss $32.930M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581001877","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581001877?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:07","pubTimestamp":1762513654,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.02) by 250 percent. This is a 200 percent increase over earnings of $0.01 per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48714254/gyre-therapeutics-q3-eps-0-03-beats-0-02-estimate-sales-30-600m-miss-32-930m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE"],"gpt_icon":0},{"id":"2581009971","title":"Gyre Therapeutics reports Q3 revenue of $30.6 million and net income of $5.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581009971","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581009971?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:00","pubTimestamp":1762513222,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc. reported revenue of $30.6 million for the third quarter of 2025, a 20% increase year-over-year, driven by growth in ETUARY sales and contributions from Etorel and Contiva. Net income for the quarter doubled to $5.9 million, while adjusted net income rose to $8.8 million. Operating income increased by 64% to $6.9 million, and basic earnings per share improved to $0.04 from $0.01 a year earlier. For the nine months ended September 30, 2025, revenues totaled $79.4 million compared to $77.9 million for the same period in 2024. The company revised its full-year 2025 revenue guidance to $115-118 million, down from $118-128 million, due to a slower-than-expected rollout of Etorel and market uncertainty related to China's centralized procurement policy. Marketing efforts were refocused on ETUARY during the third quarter, with expectations for continued ETUARY sales growth in the fourth quarter.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL7qhZlX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","BK4112","LU0314104364.USD","LU2095319765.USD","BK4139","GYRE","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","LU2210149790.SGD","LU2210150020.SGD","NDAQ","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2581090770","title":"Gyre Therapeutics: FY Revenue Guidance Revised to $115–118 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2581090770","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581090770?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:00","pubTimestamp":1762513202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nPLXA2974F:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2581090630","title":"Gyre Therapeutics: Expect to File the US Ind for Hydronidone for Treatment of Mash-Associated Liver Fibrosis in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2581090630","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581090630?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:00","pubTimestamp":1762513202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nPLXA2974F:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2581009410","title":"Gyre Therapeutics Q3 Net Income USD 5.936 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581009410","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581009410?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:00","pubTimestamp":1762513202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nPLXA2974F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2581009007","title":"Gyre Therapeutics Inc  FY2025 REV View $119.5 Mln -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2581009007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581009007?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:00","pubTimestamp":1762513202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nPLXA2974F:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2581000009","title":"Gyre Therapeutics: Guidance Reflects Slower-Than-Expected Commercialization of Etorel Due to Uncertainty Related to China’s Centralized Procurement Policy","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000009","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000009?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:00","pubTimestamp":1762513202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nPLXA2974F:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2581452009","title":"Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581452009","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581452009?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:00","pubTimestamp":1762513201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUA30KFQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2580721004","title":"Noble Financial Sticks to Their Buy Rating for Gyre Therapeutics (GYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580721004","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580721004?lang=en_us&edition=fundamental","pubTime":"2025-11-04 00:06","pubTimestamp":1762185987,"startTime":"0","endTime":"0","summary":"Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Gyre Therapeutics today and set a price target of $20.00. The company’s shares op...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/noble-financial-sticks-to-their-buy-rating-for-gyre-therapeutics-gyre-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/noble-financial-sticks-to-their-buy-rating-for-gyre-therapeutics-gyre-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","NBL"],"gpt_icon":0},{"id":"2575857677","title":"Gyre Therapeutics Subsidiary Completes Enrollment in Phase 3 Trial of Pirfenidone Capsules for Pneumoconiosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2575857677","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575857677?lang=en_us&edition=fundamental","pubTime":"2025-10-15 19:01","pubTimestamp":1760526063,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc. announced that its indirect, majority-owned subsidiary, Gyre Pharmaceuticals Co., Ltd., has completed patient enrollment in a Phase 3 clinical trial of Pirfenidone capsules for the treatment of pneumoconiosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL3KLn9V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4112","BK4588","LU2210150020.SGD","LU0314104364.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4139","NDAQ","BK4585","LU2210149790.SGD","GYRE"],"gpt_icon":0},{"id":"2575856947","title":"Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2575856947","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575856947?lang=en_us&edition=fundamental","pubTime":"2025-10-15 19:00","pubTimestamp":1760526000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nTUACHHYB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2575218812","title":"High Growth US Tech Stocks To Watch In October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575218812","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575218812?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:08","pubTimestamp":1760440088,"startTime":"0","endTime":"0","summary":"As of October 2025, the U.S. stock market has been experiencing significant volatility, with major indices like the Nasdaq and S&P 500 rebounding sharply after recent declines due to geopolitical tensions. This dynamic environment underscores the importance of identifying high-growth tech stocks that can capitalize on evolving market conditions, particularly those demonstrating resilience and innovation in response to global economic shifts.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gyre/gyre-therapeutics/news/high-growth-us-tech-stocks-to-watch-in-october-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gyre/gyre-therapeutics/news/high-growth-us-tech-stocks-to-watch-in-october-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4157","BK4139","GYRE","DAKT","PTGX"],"gpt_icon":0},{"id":"2575329146","title":"Gyre Therapeutics to Present Positive Phase 3 Trial Results of Hydronidone for Liver Fibrosis in Chronic Hepatitis B at AASLD 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575329146","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575329146?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:00","pubTimestamp":1760439619,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics to Present Positive Phase 3 Trial Results of Hydronidone for Liver Fibrosis in Chronic Hepatitis B at AASLD 2025. Gyre Therapeutics Inc. announced that it will present results from its positive Phase 3 clinical trial evaluating Hydronidone, a novel anti-fibrotic agent, for the treatment of liver fibrosis in chronic hepatitis B. The results will be presented at The Liver Meeting 2025, organized by the American Association for the Study of Liver Diseases , which is scheduled to be held from November 7-10, 2025, in Washington D.C. The study abstract, titled \"Phase 3 Trial of Hydronidone for Liver Fibrosis in Chronic Hepatitis B,\" has been selected as a Poster of Distinction and will be presented by Prof. Lungen Lu of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL9m44YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4585","BK4112","BK4139","LU2095319765.USD"],"gpt_icon":0},{"id":"2574173373","title":"Gyre Therapeutics Initiated at Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2574173373","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574173373?lang=en_us&edition=fundamental","pubTime":"2025-10-10 19:38","pubTimestamp":1760096280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GYRE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 10, 2025 07:38 ET (11:38 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2574780691","title":"Jefferies Initiates Coverage on Gyre Therapeutics With Buy Rating, $16 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2574780691","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574780691?lang=en_us&edition=fundamental","pubTime":"2025-10-10 19:31","pubTimestamp":1760095878,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (GYRE) has an average rating of Buy and mean price target of $18, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GYRE"],"gpt_icon":0},{"id":"2572378922","title":"Discovering 3 Undiscovered Gems In The US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2572378922","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572378922?lang=en_us&edition=fundamental","pubTime":"2025-10-01 01:03","pubTimestamp":1759251809,"startTime":"0","endTime":"0","summary":"As the U.S. market faces potential volatility with major stock indexes experiencing slight fluctuations ahead of a government shutdown deadline, investors are keenly observing economic indicators that could impact small-cap stocks. In such an environment, identifying lesser-known companies with strong fundamentals and growth potential can be crucial for those looking to uncover hidden opportunities in the market.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gyre/gyre-therapeutics/news/discovering-3-undiscovered-gems-in-the-us-market-6","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gyre/gyre-therapeutics/news/discovering-3-undiscovered-gems-in-the-us-market-6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SPOK","HONE","BK4132","GYRE","BK4211","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}]}}